Chief Executive, MannKind Corp.
Castagna has served as chief executive of MannKind Corp. in Westlake Village since 2017. The organization develops therapeutic products and devices designed to help people manage serious medical conditions. The company has a rapid-acting inhaled insulin, Afrezza, which treats diabetes. The company is also working on helping people with endocrine and orphan lung diseases. Earlier this year MannKind announced its eighth consecutive quarter of revenue growth. The company has also received Fast Track designation and clearance for its IND for MNKD-101 offerings.
Castagna has over 25 years of experience in the health care, pharmaceutical, biotech and specialty pharmacy industries. He first joined the MannKind as its chief commercial officer in March 2016. Prior to MannKind, he worked for Amgen, where he was vice president, global commercial lead for a portfolio of nine biosimilar drugs, and vice president, global lifecycle management. From 1997 to November 2012, Castagna was executive director of the immunoscience division of Bristol Myers Squibb. Castagna has been a member of MannKind’s board since 2017. He has a doctor of pharmacy from the Massachusetts College of Pharmacy and Health Sciences.